STOCK TITAN

Zimmer Biomet - ZBH STOCK NEWS

Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.

Overview of Zimmer Biomet

Zimmer Biomet is a globally recognized medical technology company with a deep-rooted legacy in orthopedic and musculoskeletal healthcare. With nearly 90 years of experience, the company has earned its reputation for designing, manufacturing, and marketing a comprehensive portfolio of personalized bone and joint healthcare solutions. Its range of products spans advanced joint reconstruction systems, bone and skeletal repair devices, and specialized surgical instrumentation, all engineered to help healthcare professionals deliver exceptional patient outcomes.

Core Business Areas and Product Portfolio

The company operates across multiple critical segments in orthopedics, offering solutions for joint replacement, bone repair, sports medicine, and dental reconstruction. Certain product lines emphasize large joint reconstruction while others focus on extremities and trauma care. Notably, Zimmer Biomet integrates digital technologies, robotics, and artificial intelligence into its products, enabling precision in surgery and customized treatment strategies. This integration of technology ensures that every product is backed by clinical expertise and rigorous surgical validation.

Technological Innovation and Clinical Integration

Zimmer Biomet’s commitment to innovation is evident in its incorporation of digital and robotic solutions that enhance surgical accuracy and operational efficiency. The company has successfully linked its traditional orthopedic expertise with emerging technologies such as AI-powered surgical guidance and handheld robotic systems. This synthesis supports an environment where surgeons can rely on real-time data and imaging to improve the precision of implant placement and overall surgical workflow. The firm’s emphasis on advanced technologies not only underpins its product development strategy but also reinforces its position as a trusted name in musculoskeletal care.

Global Presence and Market Position

With operations in more than 25 countries and sales across over 100 markets, Zimmer Biomet serves a diverse global clientele of hospitals, clinics, and orthopedic centers. This widespread reach reinforces the company’s status as an authoritative source of innovative orthopedic solutions. The company has consistently differentiated itself in competitive markets through strategic acquisitions and robust technological enhancements, which have expanded its portfolio and market footprint in regions including the United States, Europe, and Asia.

Expertise, Experience, and Authoritativeness

Zimmer Biomet’s nearly nine-decade history in orthopedic innovation is supported by decades of clinical research and surgical partnerships. The company’s reputation is founded on its rigorous approach to ensuring that its products not only meet but exceed the demanding standards of modern orthopedic surgery. By continuously evolving its technological capabilities and investing in research and development, Zimmer Biomet exemplifies expertise and trustworthiness in delivering sophisticated, customer-centric healthcare solutions.

Operational Excellence and Strategic Differentiation

The company’s business model is built on direct relationships with healthcare providers and relies on a comprehensive product ecosystem that balances high-quality implantable devices with integrated digital technology solutions. This approach not only drives improved patient outcomes but also supports enhanced surgical workflows and operational efficiencies. Through strategic partnerships and acquisitions, Zimmer Biomet has ensured that its service offerings are both diverse and complementary, allowing for the incremental and sustainable growth of its core orthopedic business.

Conclusion

In summary, Zimmer Biomet stands as a cornerstone in the orthopedic industry, combining a storied legacy with modern innovations in digital, robotic, and AI-enabled surgical solutions. Its comprehensive portfolio, global reach, and commitment to clinical excellence make it an essential contributor to advancements in musculoskeletal health. For investors and industry analysts, understanding Zimmer Biomet’s strategic approach and technological integration is key to appreciating its enduring impact on orthopedic care and surgery.

Rhea-AI Summary

Zimmer Biomet Holdings, Inc. reported first quarter net sales of $1.889 billion, with a 3.2% increase over the prior year. Diluted earnings per share were $0.84, adjusted diluted earnings per share were $1.94. Recent highlights include FDA clearances for innovative products and partnerships with pickleball organizations. The company reaffirmed its full-year 2024 financial guidance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
-
Rhea-AI Summary
Zimmer Biomet partners with top pickleball organizations in the US to promote joint health and movement, targeting the 48.3 million players and fans. The company aims to be a trusted partner for joint replacement, focusing on the older demographic in the sport.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
none
-
Rhea-AI Summary
Zimmer Biomet Holdings, Inc. (ZBH) will webcast its first quarter earnings conference call on May 2, 2024. The quarterly results will be released at 6:30 a.m. ET, with the webcast at 8:30 a.m. ET. Investors can access the live audio webcast on Zimmer Biomet's Investor Relations website. Dial-in options are available for U.S., Canada, and international participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
Rhea-AI Summary
Zimmer Biomet Holdings, Inc. announces FDA clearance for ROSA® Shoulder System, the world's first robotic surgery system for shoulder replacement. The system aims to improve surgical accuracy and efficiency, offering flexibility in total shoulder replacement techniques. ROSA Shoulder integrates with Signature™ ONE Surgical Planning System 2.0 for personalized surgical planning and real-time intra-operative data to reduce complications. Commercial availability in the U.S. is expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
-
Rhea-AI Summary
Zimmer Biomet Holdings, Inc. (ZBH) declares a quarterly cash dividend of $0.24 per share for the first quarter of 2024, approved by the Board of Directors. This move reflects the company's commitment to rewarding its stockholders and maintaining financial stability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
dividends
-
Rhea-AI Summary
Zimmer Biomet Holdings, Inc. signs the Zero Health Gaps Pledge to address health disparities by integrating health equity into its core strategies. The newly established Health Equity division focuses on reducing healthcare inequities, tracking progress, and collaborating on community-based solutions. The division aims to increase patient access to quality care in underserved communities through a Community Centered Care framework and partnerships with healthcare institutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
none
Rhea-AI Summary
Zimmer Biomet showcases innovative products at AAOS meeting, featuring ROSA Robotics for pending 510(k) clearance, Persona OsseoTi Keel Tibia, and HAMMR Automatic Hip Impaction System. The company highlights its commitment to transformative clinical care and customer-centric solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
none
-
Rhea-AI Summary
Zimmer Biomet Holdings, Inc. reported a 6.3% increase in net sales for the fourth quarter and a 6.5% increase for the full year. Full-year diluted earnings per share were $4.88, and adjusted diluted earnings per share were $7.55. The company provided full-year 2024 financial guidance with projected revenue change of 4.5% - 5.5% and adjusted diluted EPS of $8.00 - $8.15.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
-
Rhea-AI Summary
Zimmer Biomet Holdings, Inc. (ZBH) has announced its fourth quarter earnings conference call and webcast on February 8, 2024. The live audio webcast will be accessible via the company's Investor Relations website. Additionally, an in-person product showcase event for investors and analysts will be held on February 13, 2024, at the American Academy of Orthopaedic Surgeons Conference in San Francisco.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
Rhea-AI Summary
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) appoints Louis A. Shapiro, former President and CEO of Hospital for Special Surgery, to the Board, leveraging his extensive industry leadership experience and customer perspective.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
management

FAQ

What is the current stock price of Zimmer Biomet (ZBH)?

The current stock price of Zimmer Biomet (ZBH) is $97.27 as of April 15, 2025.

What is the market cap of Zimmer Biomet (ZBH)?

The market cap of Zimmer Biomet (ZBH) is approximately 19.9B.

What is Zimmer Biomet's primary focus?

Zimmer Biomet specializes in designing, manufacturing, and marketing orthopedic and musculoskeletal healthcare solutions, including joint reconstruction and bone repair products.

How does Zimmer Biomet integrate technology into its products?

The company incorporates digital innovations, robotic systems, and AI-driven surgical guidance to enhance precision and improve surgical workflows in orthopedic procedures.

What are the major product categories offered by Zimmer Biomet?

Zimmer Biomet offers a wide range of products including implants for joint replacement, bone and skeletal repair devices, sports medicine solutions, and surgical instrumentation.

How does Zimmer Biomet maintain its industry reputation?

With nearly 90 years of experience, the company builds on a legacy of rigorous clinical research, continuous innovation, and strategic global partnerships, ensuring high-quality, trusted healthcare solutions.

What distinguishes Zimmer Biomet from its competitors?

Its integrated approach of combining advanced technological solutions with a comprehensive product portfolio and deep clinical expertise differentiates Zimmer Biomet in the competitive orthopedic market.

In which global markets does Zimmer Biomet operate?

Zimmer Biomet serves a global market with operations in over 25 countries and sales in more than 100 regions, ensuring a broad international presence and influence.

How does Zimmer Biomet support healthcare professionals?

The company offers innovative, clinically validated orthopedic solutions that improve surgical outcomes, streamline operative efficiency, and support enhanced patient care.

What role do strategic partnerships and acquisitions play for Zimmer Biomet?

Strategic partnerships and acquisitions have allowed Zimmer Biomet to broaden its product range and technological capabilities, reinforcing its market position and enabling cross-functional innovation in the orthopedic space.
Zimmer Biomet

NYSE:ZBH

ZBH Rankings

ZBH Stock Data

19.90B
197.52M
0.2%
93.68%
3.54%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
WARSAW